Last reviewed · How we verify
NCT05775510: SENSE SCS
Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chronic Pain
trial testing Commercially available neurostimulation systems in Pain, Intractable in 91 participants. Terminated before completion.
29 May 2025
Quick facts
| Lead sponsor | MedtronicNeuro |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 91 |
| Start date | 25 April 2023 |
| Primary completion | 29 May 2025 |
| Estimated completion | 29 May 2025 |
| Sites | 10 locations across United States |
Drugs / interventions tested
- Commercially available neurostimulation systems
Conditions studied
- Pain, Intractable — all drugs for Pain, Intractable →
- Pain, Chronic — all drugs for Pain, Chronic →
Sponsor
MedtronicNeuro — full company profile →
Who can join
18 and older, any sex, with Pain, Intractable or Pain, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Medtronic, Inc. is sponsoring the SENSE SCS clinical study, a prospective, multi-center, post-market, non-randomized, observational study with a hybrid decentralized model of execution, utilizing a mobile application for the collection of patient reported outcomes (PROs). The purpose of the study is to evaluate workflow of a mobile application for collection of PROs and to gather data on patient experience with spinal cord stimulation therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05775510
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pain, Intractable
Currently open trials in the same condition.
- NCT07095036 — Sensory Spinal Cord Stimulation · NA · recruiting
- NCT06596681 — A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain · EARLY_PHASE1 · recruiting
- NCT05398003 — Medullary Stimulation for the Treatment of Refractory Neck Pain (S2M) · NA · recruiting
- NCT05761392 — APP-based Precise Management System of Chronic Intractable Pain · NA · recruiting
- NCT04727216 — Intermittent vs. Continuous Dorsal Root Ganglion Stimulation · NA · active not recruiting
Other MedtronicNeuro trials
Trials by the same sponsor.
- NCT05226286 — Evaluation of Implantable Tibial Neuromodulation Pivotal Study (TITAN 2) · NA · completed
- NCT05200923 — Pelvic Health Electrically Evoked Recording (PEER) 2 Study · NA · recruiting
- NCT05177354 — Medtronic Closed-Loop Spinal Cord Stimulation System · NA · completed
- NCT07106242 — Adaptive Deep Brain Stimulation (aDBS) Study (Early Adapter) Part II · NA · completed
- NCT04873271 — Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05775510 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MedtronicNeuro
- Last refreshed: 14 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05775510.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing